At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
hydroxychloroquine +2 moredrug
Likely dose
hydroxychloroquine 1200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
In Brief
A Phase 1 clinical trial evaluating hydroxychloroquine, entinostat, and 1 other intervention for Colorectal Cancer. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartOct 2017
Primary CompletionJun 2020
TodayJul 2026
First PostedJul 12, 2017
Enrollment StartOct 2, 2017
Primary CompletionJun 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.0 years ago
Interventions
hydroxychloroquinedrug
600-1200mg daily
entinostatdrug
3-5mg weekly
regorafenibdrug
160mg daily